Cardiovascular Medicine and Haematology articles for Australia

Time frame: 1 May 2025 - 30 April 2026

View topic

Count: 147

Article ‘Count’ for Cardiovascular Medicine and Haematology.

Journal Count Share
1 0.08
Interaction between dietary cholesterol intake and genetic variants for cholesterol absorption in relation to coronary artery disease mortality: a prospective analysis in the Singapore Chinese Health Study 0.08
2 2.00
The effect of damp housing on psychological distress: does respiratory health matter? 1.00
The protective effect of housing affordability on childhood asthma risk: a longitudinal fixed-effects analysis 1.00
1 0.63
Reproductive factors and the risk of incident peripheral arterial disease hospitalisation or death: A cohort study of UK Biobank participants 0.63
8 0.56
Idiopathic Pulmonary Fibrosis Risk Loci in East Asian Populations Mirror those of European Populations 0.05
International validation of electronic nose technology as diagnostic tool for fibrotic interstitial lung diseases 0.18
Phenotyping Asthma and/or COPD Using 129Xe MRI and Comprehensive Physiologic Testing. 0.04
Outcomes of a Typical Fibrotic Hypersensitivity Pneumonitis Pattern on Chest Computed Tomography 0.02
Impact of Elexacaftor/Tezacaftor/Ivacaftor on Glucose Tolerance and Abnormal Glucose Metabolism: A Phase 3b, Open-Label Clinical Trial. 0.13
A Large-Scale Single-Cell Atlas Reveals the Peripheral Immune Panorama of Bacterial Pneumonia. 0.05
Performance Characteristics for Physiological Measures of Progressive Pulmonary Fibrosis. 0.03
Long-Term Safety and Efficacy of Elexacaftor/Tezacaftor/Ivacaftor in Children ≥6 Years with Cystic Fibrosis and at Least One F508del Allele: A 192-Week, Phase 3, Open-Label Extension Study. 0.06
1 0.04
TEG® 6s heparin neutralization cartridge for hemostatic assessment of patients undergoing cardiovascular surgery. 0.04
1 0.75
Self‐Assembled Metal‐Polyphenol Colchicine Nanoparticles Targeting Oxidative Stress and Inflammation for Treatment of Atherosclerosis 0.75
1 1.00
The Limit of Detection in the Emergency Department Trial (LEGEND): A Stepped-Wedge Cluster Randomized Trial to Rule Out Acute Myocardial Infarction and Reduce Hospital Length of Stay for Patients Presenting to the Emergency Department 1.00
4 1.10
Ultraprecision therapy for type 1 vs type 2 CALR+ MPN by dual epitope targeting that restores ruxolitinib sensitivity 0.92
The landscape and evolution of clonal hematopoiesis in chronic lymphocytic leukemia 0.07
Clinical phenotype and pathophysiological mechanisms underlying qualitative low VWF 0.03
The MURANO study: final analysis and retreatment/crossover substudy results of VenR for patients with relapsed/refractory CLL 0.09
1 0.33
Haematopoietic stem cell transplant versus immune-reconstitution therapy in relapsing multiple sclerosis 0.33
1 0.08
An infant nasal microbial gene atlas uncovers intervention-driven microbiome shifts and salt-resistant pathogen expansion 0.08
10 5.89
OSA Is Associated With Enhanced Coronary Collateral Circulation and Reduced Myocardial Injury During Acute Coronary Syndromes 0.07
Sex does not modify prediction of asthma attacks by clinical risk factors and Type-2 biomarkers 0.04
Recovery rate from exertional desaturation is associated with disease progression and mortality risk in patients with fibrotic interstitial lung disease 0.09
Relationship between Framingham 10-year cardiovascular disease risk score and pulse wave amplitude drop characteristics in a sleep clinic cohort. 1.00
International stakeholder engagement on clinical care and research for sleep assessment and nocturnal hypoxaemia in pulmonary fibrosis 0.76
Pediatric bronchiectasis action management plan to improve clinical outcomes: An RCT 1.00
Novel hypoglossal stimulation markedly improves airflow and airway collapsibility in OSA 1.00
Failure to report sex-specific risk factors in heart failure with preserved ejection fraction research: a scoping review 1.00
Geographical Distribution of Phase II/III Pharmaceutical Randomised Controlled Trials in Adults with Interstitial Lung Disease 0.83
Prediction pathway for severe asthma exacerbations: a Bayesian Network analysis 0.09
10 1.58
The Natural History of Massive Left Ventricular Hypertrophy in Pediatric Hypertrophic Cardiomyopathy: A Multiregistry Analysis. 0.11
Differences in Disease Trajectory, Comorbidities, and Mortality in Sarcomeric and Nonsarcomeric Hypertrophic Cardiomyopathy. 0.09
Natural History of Patients With Histologically Proven Acute Eosinophilic Myocarditis. 0.02
Bradycardia in Athletes: Prevalence, Mechanisms, and Risks. 0.63
Efficacy and Safety of Very Low Achieved LDL-Cholesterol in Patients with Prior Ischemic Stroke. 0.08
Heart Stress and Blood Pressure Management in Older Adults: Post Hoc Analysis of the ASPREE Trial. 0.44
Hypercontractility and Oxidative Stress Drive Creatine Kinase Dysfunction in Hypertrophic Cardiomyopathy. 0.08
Drug-Eluting Resorbable Scaffold Versus Balloon Angioplasty for Below-the-Knee Peripheral Artery Disease: 2-Year Results From the LIFE-BTK Trial. 0.05
Prognostic Role of Myocarditis-Like Episodes and Their Treatment in Patients With Pathogenic Desmoplakin Variants. 0.06
Effect of Remote Ischemic Preconditioning on Myocardial Injury in Noncardiac Surgery: the PRINCE Randomized Clinical Trial. 0.02
2 1.33
Incidence of Type 2 Diabetes With Verapamil Compared With Other Calcium Channel Blockers. 1.00
International Variation in Case Fatality After Major Coronary or Cerebrovascular Events in Individuals With Type 2 Diabetes: Evidence From ADVANCE, TECOS, and EXSCEL. 0.33
1 0.13
Co-exposure to multiple fine particulate matter constituents and adults obstructive sleep apnoea (OSA) in Southern China 0.13
4 2.19
Trajectories of Meteorological and Air Pollution Exposures during pregnancy and risk of Childhood Asthma: A Population-Based Cohort Study 0.05
Health benefits of traffic emissions controls in Melbourne, Australia 1.00
Ten-year exposure to household air pollution is associated with obstructive sleep apnoea 1.00
Exposure-effect of PFOS and PFOA on lung function: An integrated approach with epidemiological, cellular, and animal studies 0.14
19 5.64
Cardiac resynchronization therapy with or without atrioventricular node ablation in atrial fibrillation: the CAAN-AF trial 0.81
New-onset postoperative atrial fibrillation management and outcomes: the VISION Cardiac Surgery cohort 0.04
Stroke and systemic embolism following atrial fibrillation ablation: the EMBOL-AF Global Registry 0.03
Risk prediction in patients with heart failure with preserved ejection fraction: the LIFE-Preserved model 0.01
Laminopathies: natural history and risk prediction of heart failure 0.01
Heart failure with preserved ejection fraction in adults with congenital heart disease 0.08
Peripheral autonomic dysregulation in response to standing: a new form associated with cardiovascular disease, mobility reduction, and cognitive alterations 0.54
Adults with Fontan circulation: prognostic value of exercise pulmonary vascular resistance index 0.37
Catecholaminergic polymorphic ventricular tachycardia mediated by ryanodine receptor 2: a validated risk stratification 0.05
C-reactive protein and cardiovascular risk among women with no standard modifiable risk factors: evaluating the ‘SMuRF-less but inflamed’ 0.20
Withdrawal of heart failure therapy after atrial fibrillation rhythm control with ejection fraction normalization: the WITHDRAW-AF trial 1.00
Aspirin, cardiovascular events, and major bleeding in older adults: extended follow-up of the ASPREE trial 0.69
Titin-related familial dilated cardiomyopathy: factors associated with disease onset 0.25
Cardiovascular benefit of continuous positive airway pressure according to high-risk obstructive sleep apnoea: a multi-trial analysis 0.22
Colchicine for secondary prevention of vascular events: a meta-analysis of trials 0.12
First myocardial infarction: risk factors, symptoms, and medical therapy 0.07
Atrial fibrillation in former world-class rowers: role of environmental and genetic factors 0.81
Immune checkpoint inhibitor-associated myocarditis: a novel risk score 0.02
The Australian–New Zealand SCAD observational cohort study: major adverse cardiovascular events are associated with ticagrelor combined with aspirin, FMD, and history of stroke 0.33
1 0.13
Comorbidity of asthma and attention deficit hyperactivity disorder in childhood: causal, shared early-life risk factors, or shared genetic liability? 0.13
2 0.13
Adherence to positive airway pressure therapy and healthcare resource utilization and costs among patients with obstructive sleep apnea and obesity 0.11
Impact of preoperative body mass index on postoperative outcomes in infective endocarditis: a multicenter analysis of 4801 consecutive patients 0.02
5 1.33
Evolocumab to Reduce First Major Cardiovascular Events in Patients Without Known Significant Atherosclerosis and With Diabetes 0.00
Cryopreserved vs Liquid-Stored Platelets for the Treatment of Surgical Bleeding 0.95
Coronary Computed Tomography Angiography in Prediction of First Coronary Events 0.02
SGLT2 Inhibitors and Kidney Outcomes by Glomerular Filtration Rate and Albuminuria 0.18
Effects of Sodium Glucose Cotransporter 2 Inhibitors by Diabetes Status and Level of Albuminuria 0.19
7 1.49
BRUIN CLL-313: Randomized Phase III Trial of Pirtobrutinib Versus Bendamustine Plus Rituximab in Untreated Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma. 0.05
Pirtobrutinib Versus Ibrutinib in Treatment-Naïve and Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma. 0.07
FLIPI24: A Modern Prognostic Model and Clinical Trial Enrichment Tool for Newly Diagnosed Follicular Lymphoma. 0.08
Glofitamab Combined With Pola-R-CHP or R-CHOP as First Therapy in Younger Patients With High-Risk Large B-Cell Lymphoma: Results From the COALITION Study. 1.00
Phase III Trial of Pirtobrutinib Versus Idelalisib/Rituximab or Bendamustine/Rituximab in Covalent Bruton Tyrosine Kinase Inhibitor-Pretreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BRUIN CLL-321). 0.04
Zanubrutinib and Venetoclax for Patients With Treatment-Naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma With and Without Del(17p)/TP53 Mutation: SEQUOIA Arm D Results. 0.16
Acalabrutinib Plus Bendamustine-Rituximab in Untreated Mantle Cell Lymphoma. 0.10
1 0.89
Treatment of Pseudomonas by Removal of Cloaking Antibodies: Is Common Polysaccharide Antigen a Factor? 0.89
9 5.18
Fontan pathway diameter in adults undergoing exercise catheterization: Association with hemodynamics, exercise capacity, and liver scores 0.30
Long-term outcomes of aortic valve repair in children after infancy 1.00
Second cross-clamp in less invasive mitral valve repair for degenerative mitral regurgitation: Predictors and outcomes 0.05
Development of a patient-specific Fontan failure risk calculator using machine learning—a step toward personalized medicine 0.80
Intraoperative predictors of left atrioventricular valve reoperation after repair of complete atrioventricular septal defect 1.00
Shifting strategies to address systemic outflow tract obstruction in single ventricle anatomy with transposed great arteries 0.88
Platelet Responsiveness to Aspirin in Pediatric Patients Undergoing Cardiac Surgery – A Prospective Cohort Study 1.00
Early extraction versus conservative management in patients with non-infected cardiac implantable electronic devices undergoing cardiac surgery for left-sided infective endocarditis: Insights from the multicentric CAMPAIGN Registry 0.04
The American Association for Thoracic Surgery (AATS) 2025 Expert Consensus Document: Management of Ebstein anomaly in children and adults 0.12
11 3.29
Preferences for Antihypertensive Prescribing in Older Adults 1.00
Echocardiographic Diastolic Function Grading in HFpEF Testing the Updated 2025 ASE Criteria 0.11
Heart Failure Quality of Care Among Asian Patients in the United States 0.06
Loss of Y Chromosome and Major Cardiovascular Events in a Prospective Study of Older Men 0.79
Proactive Management and Treatment of Aortic Stenosis: An International Expert Perspective 0.03
Incremental Value of Cardiac Myosin-Binding Protein C for the Early Diagnosis of Acute Myocardial Infarction 0.02
Impact of Obicetrapib on Major Adverse Cardiovascular Events in High-Risk Patients A Pooled Analysis 0.20
Natriuretic Peptides, Body Mass Index, and Clinical Outcomes in Heart Failure with Mildly Reduced or Preserved Ejection Fraction 0.06
Clinical Outcomes of Conduction System Pacing vs Right Ventricular Septal Pacing in Atrioventricular Block The CSPACE Randomized Controlled Trial 0.95
Global Impact of Fixed-Dose Combination Therapies on Cardiovascular Mortality and Events, 2023-2050 A Modeling Study 0.04
Differences in Arterial Events in Vascular Ehlers-Danlos, Loeys-Dietz, and Marfan Syndrome 0.04
1 1.00
Meeting trial eligibility in follicular lymphoma patients is associated with overall survival but not progression-free survival 1.00
9 2.15
MicroRNA-30c analog C2 decreases plasma cholesterol and atherosclerosis without causing liver injury in preclinical studies 0.03
Glycaemic variability underlies myocyte dysfunction and myocardial injury risk in diabetes 0.90
NK cells promote cardiac cell death and regulate myelopoiesis in myocardial infarction 0.03
CXCR3 is associated with T-cell-induced heart damage in acute rheumatic fever 0.30
Clusters of vascular aging manifestations predict incident cardiovascular events in the community 0.06
Airway immune profiles and therapeutic implications of IGF1 in eosinophilic granulomatosis with polyangiitis 0.04
Single cell spatial transcriptomics integration deciphers the morphological heterogeneity of atherosclerotic carotid arteries 0.03
Inhibiting CD36 palmitoylation improves cardiac function post-infarction by regulating lipid metabolic homeostasis and autophagy 0.02
Global warming may increase the burden of obstructive sleep apnea 0.73
1 0.06
Aberrant cellular communities underlying disease heterogeneity in chronic obstructive pulmonary disease 0.06
6 0.57
Zodasiran for cholesterol and triglyceride lowering in patients with hyperlipidemia: final report of phase 1 basket trial 0.20
Socioeconomic and energy transition disparities in air pollution-related mortality across Europe 0.06
Obicetrapib in patients with heterozygous familial hypercholesterolemia: the BROOKLYN randomized clinical trial 0.13
Tirzepatide on obstructive sleep apnea-related cardiometabolic risk: secondary outcomes of the SURMOUNT-OSA randomized trial 0.08
Global, regional, and national burden of chronic respiratory diseases and impact of the COVID-19 pandemic, 1990–2023: a Global Burden of Disease study 0.06
Antibody-mediated LOX-1 inhibition in patients with residual inflammation after myocardial infarction: a randomized phase 2 trial 0.04
1 0.09
Effect of climate-driven childhood sleep erosion on potential regional economic inequality 0.09
1 0.08
The impact of the Lancet Commission definition of obesity on its prevalence and implications on long-term cardiovascular-kidney-metabolic outcomes in East Asians: Observational study of two community-based cohorts 0.08
1 0.05
Deep-learning analysis of 3D microarchitectural remodeling in hypertrophic cardiomyopathy 0.05
2 1.66
Atopy-related immune profiles are subject to genetic influence as evaluated using school-aged twin pairs 0.81
NLRP3 inflammasome–driven hemophagocytic lymphohistiocytosis occurs independent of IL-1β and IL-18 and is targetable by BET inhibitors 0.84
3 0.94
Personal network inference identifies children at risk of recurrent wheezing and asthma 0.91
Nasal gene expression shows a distinct signature in T2-high asthma but not in T2-low disease 0.01
Genetic characterization of preschool wheeze phenotypes 0.02
7 0.71
Epcoritamab, lenalidomide, and rituximab versus lenalidomide and rituximab for relapsed or refractory follicular lymphoma (EPCORE FL-1): a global, open-label, randomised, phase 3 trial 0.07
Tafasitamab, lenalidomide, and rituximab in relapsed or refractory follicular lymphoma (inMIND): a global, phase 3, randomised controlled trial 0.05
Effect of evolocumab on saphenous vein graft patency after coronary artery bypass surgery (NEWTON-CABG CardioLink-5): an international, randomised, double-blind, placebo-controlled trial 0.05
Clopidogrel versus aspirin for secondary prevention of coronary artery disease: a systematic review and individual patient data meta-analysis 0.03
Blood pressure-lowering efficacy of antihypertensive drugs and their combinations: a systematic review and meta-analysis of randomised, double-blind, placebo-controlled trials 0.37
Spironolactone versus placebo in patients undergoing maintenance dialysis (ACHIEVE): an international, parallel-group, randomised controlled trial 0.08
Fixed-dose combination of obicetrapib and ezetimibe for LDL cholesterol reduction (TANDEM): a phase 3, randomised, double-blind, placebo-controlled trial 0.06
1 0.13
Zodasiran, an RNAi therapeutic targeting ANGPTL3, for treating patients with homozygous familial hypercholesterolaemia (GATEWAY): an open-label, randomised, phase 2 trial 0.13
1 0.88
Individual-level and community-level factors for 10-year cardiovascular disease risk in Ethiopia: a retrospective, population-based, cross-sectional, observational study 0.88
6 0.88
Three Low-Dose Antihypertensive Agents in a Single Pill after Intracerebral Hemorrhage 0.27
Inhaled Treprostinil for Idiopathic Pulmonary Fibrosis 0.11
Bleeding Risk with Apixaban vs. Rivaroxaban in Acute Venous Thromboembolism 0.16
Phase 1 Trial of CRISPR-Cas9 Gene Editing Targeting ANGPTL3 0.14
Antithrombotic Therapy after Successful Catheter Ablation for Atrial Fibrillation 0.07
Safety and Efficacy of Obicetrapib in Patients at High Cardiovascular Risk 0.13
4 2.24
Multidisciplinary, non-pharmacological breathlessness intervention service for patients with moderately severe to severe COPD: a randomised controlled trial 1.00
Mobile health pulmonary rehabilitation (m-PR): a randomised controlled equivalence trial 1.00
Inhalational exposures associated with risk of interstitial lung disease: a systematic review and meta-analysis 0.09
Impact of long-term non-invasive ventilation on severe exacerbations and survival in COPD: a French nationwide cohort study using multistate models 0.15

Numerical information only (in the tables above) is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International.